A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...
Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.
Women who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone.
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...
AVAILABLE 24/7. WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE EFFECTIVENESS OF A NANOPARTICLE GEL AND ITS ABILITY TO TREAT ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
An expert discusses how multidisciplinary collaboration can be enhanced through shared knowledge of available drugs and biomarkers among oncologists and pathologists, standardized interpretation ...
In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback